Radical surgery versus organ preservation via short-course radiotherapy followed by transanal endoscopic microsurgery for early-stage rectal cancer (TREC): a randomised, open-label feasibility study.


Journal

The lancet. Gastroenterology & hepatology
ISSN: 2468-1253
Titre abrégé: Lancet Gastroenterol Hepatol
Pays: Netherlands
ID NLM: 101690683

Informations de publication

Date de publication:
02 2021
Historique:
received: 13 08 2020
revised: 12 10 2020
accepted: 13 10 2020
pubmed: 15 12 2020
medline: 20 2 2021
entrez: 14 12 2020
Statut: ppublish

Résumé

Radical surgery via total mesorectal excision might not be the optimal first-line treatment for early-stage rectal cancer. An organ-preserving strategy with selective total mesorectal excision could reduce the adverse effects of treatment without substantially compromising oncological outcomes. We investigated the feasibility of recruiting patients to a randomised trial comparing an organ-preserving strategy with total mesorectal excision. TREC was a randomised, open-label feasibility study done at 21 tertiary referral centres in the UK. Eligible participants were aged 18 years or older with rectal adenocarcinoma, staged T2 or lower, with a maximum diameter of 30 mm or less; patients with lymph node involvement or metastases were excluded. Patients were randomly allocated (1:1) by use of a computer-based randomisation service to undergo organ preservation with short-course radiotherapy followed by transanal endoscopic microsurgery after 8-10 weeks, or total mesorectal excision. Where the transanal endoscopic microsurgery specimen showed histopathological features associated with an increased risk of local recurrence, patients were considered for planned early conversion to total mesorectal excision. A non-randomised prospective registry captured patients for whom randomisation was considered inappropriate, because of a strong clinical indication for one treatment group. The primary endpoint was cumulative randomisation at 12, 18, and 24 months. Secondary outcomes evaluated safety, efficacy, and health-related quality of life assessed with the European Organisation for Research and Treatment of Cancer (EORTC) QLQ C30 and CR29 in the intention-to-treat population. This trial is registered with the ISRCTN Registry, ISRCTN14422743. Between Feb 22, 2012, and Dec 19, 2014, 55 patients were randomly assigned at 15 sites; 27 to organ preservation and 28 to radical surgery. Cumulatively, 18 patients had been randomly assigned at 12 months, 31 at 18 months, and 39 at 24 months. No patients died within 30 days of initial treatment, but one patient randomly assigned to organ preservation died within 6 months following conversion to total mesorectal excision with anastomotic leakage. Eight (30%) of 27 patients randomly assigned to organ preservation were converted to total mesorectal excision. Serious adverse events were reported in four (15%) of 27 patients randomly assigned to organ preservation versus 11 (39%) of 28 randomly assigned to total mesorectal excision (p=0·04, χ Short-course radiotherapy followed by transanal endoscopic microsurgery achieves high levels of organ preservation, with relatively low morbidity and indications of improved quality of life. These data support the use of organ preservation for patients considered unsuitable for primary total mesorectal excision due to the short-term risks associated with this surgery, and support further evaluation of short-course radiotherapy to achieve organ preservation in patients considered fit for total mesorectal excision. Larger randomised studies, such as the ongoing STAR-TREC study, are needed to more precisely determine oncological outcomes following different organ preservation treatment schedules. Cancer Research UK.

Sections du résumé

BACKGROUND
Radical surgery via total mesorectal excision might not be the optimal first-line treatment for early-stage rectal cancer. An organ-preserving strategy with selective total mesorectal excision could reduce the adverse effects of treatment without substantially compromising oncological outcomes. We investigated the feasibility of recruiting patients to a randomised trial comparing an organ-preserving strategy with total mesorectal excision.
METHODS
TREC was a randomised, open-label feasibility study done at 21 tertiary referral centres in the UK. Eligible participants were aged 18 years or older with rectal adenocarcinoma, staged T2 or lower, with a maximum diameter of 30 mm or less; patients with lymph node involvement or metastases were excluded. Patients were randomly allocated (1:1) by use of a computer-based randomisation service to undergo organ preservation with short-course radiotherapy followed by transanal endoscopic microsurgery after 8-10 weeks, or total mesorectal excision. Where the transanal endoscopic microsurgery specimen showed histopathological features associated with an increased risk of local recurrence, patients were considered for planned early conversion to total mesorectal excision. A non-randomised prospective registry captured patients for whom randomisation was considered inappropriate, because of a strong clinical indication for one treatment group. The primary endpoint was cumulative randomisation at 12, 18, and 24 months. Secondary outcomes evaluated safety, efficacy, and health-related quality of life assessed with the European Organisation for Research and Treatment of Cancer (EORTC) QLQ C30 and CR29 in the intention-to-treat population. This trial is registered with the ISRCTN Registry, ISRCTN14422743.
FINDINGS
Between Feb 22, 2012, and Dec 19, 2014, 55 patients were randomly assigned at 15 sites; 27 to organ preservation and 28 to radical surgery. Cumulatively, 18 patients had been randomly assigned at 12 months, 31 at 18 months, and 39 at 24 months. No patients died within 30 days of initial treatment, but one patient randomly assigned to organ preservation died within 6 months following conversion to total mesorectal excision with anastomotic leakage. Eight (30%) of 27 patients randomly assigned to organ preservation were converted to total mesorectal excision. Serious adverse events were reported in four (15%) of 27 patients randomly assigned to organ preservation versus 11 (39%) of 28 randomly assigned to total mesorectal excision (p=0·04, χ
INTERPRETATION
Short-course radiotherapy followed by transanal endoscopic microsurgery achieves high levels of organ preservation, with relatively low morbidity and indications of improved quality of life. These data support the use of organ preservation for patients considered unsuitable for primary total mesorectal excision due to the short-term risks associated with this surgery, and support further evaluation of short-course radiotherapy to achieve organ preservation in patients considered fit for total mesorectal excision. Larger randomised studies, such as the ongoing STAR-TREC study, are needed to more precisely determine oncological outcomes following different organ preservation treatment schedules.
FUNDING
Cancer Research UK.

Identifiants

pubmed: 33308452
pii: S2468-1253(20)30333-2
doi: 10.1016/S2468-1253(20)30333-2
pmc: PMC7802515
pii:
doi:

Banques de données

ISRCTN
['ISRCTN14422743']

Types de publication

Comparative Study Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

92-105

Subventions

Organisme : Cancer Research UK
ID : 11436
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 28301
Pays : United Kingdom
Organisme : Cancer Research UK
ID : CRUK/09/032
Pays : United Kingdom

Investigateurs

Gina Brown (G)
Peter Antonio (P)
Alex Vince (A)
Nick Hilken (N)
Chakanaka Sidile (C)
Adrian Wilcockson (A)
Richard Peto (R)
Tom Crosby (T)
Brendan Moran (B)
Julie Olliff (J)
Katti Ashok (K)
Simone Slawik (S)
Andrew Smethurst (A)
Rajaram Sripadam (R)
Veena Tagore (V)
Monica Terlizzo (M)
Bearn Philip (B)
Robert Davies (R)
Susan Dodd (S)
Sharadah Essapen (S)
Pasha Nisar (P)
Alexandra Stewart (A)
Jonathan Trickett (J)
Bansal Ashish (B)
Peter Billings (P)
Palanichamy Chandran (P)
Conor Corr (C)
Edward Favill (E)
Simon Gollins (S)
Peter Marsh (P)
Andrew Maw (A)
Rakha Neupane (R)
Ramesh Rajagopal (R)
Rachel Cooper (R)
John Griffith (J)
Paul Hatfield (P)
Andy Lowe (A)
Julian Ostrowski (J)
Jonathan Robinson (J)
Rhian Simpson (R)
Richard Adams (R)
Robert Bleehen (R)
Michael Davies (M)
Meleri Morgan (M)
Darren Boone (D)
Nicola Lacey (N)
Ian Seddon (I)
Bruce Sizer (B)
Helen Stunell (H)
Shaobin Wu (S)
Maher Hadaki (M)
Dominic Blunt (D)
Susan Cleator (S)
Ara Darzi (A)
Robert Goldin (R)
Paul Ziprin (P)
Mike Dobson (M)
Mark Pitt (M)
Shabbir Susnerwala (S)
Deborah Williamson (D)
Georgina Howarth (G)
Stephen Lee (S)
Paul Wright (P)
Tim Hoare (T)
Alan Horgan (A)
Fiona McDonald (F)
Stephanie Needham (S)
John Scott (J)
Timothy Simmons (T)
Debashis Biswas (D)
James Hernon (J)
Gaurav Kapur (G)
Sandeep Kapur (S)
James Sington (J)
Christopher Speakman (C)
William Stebbings (W)
Stuart Williams (S)
Madhavi Adusumalli (M)
Anil Agarwal (A)
David Borowski (D)
Dharmendra Garg (D)
Talvinder Gill (T)
Mohammed Hegab (M)
Catherine Hobday (C)
Veena Rao (V)
Jyotsna Shrimankar (J)
Mohamed Tabaqchali (M)
David Wilson (D)
Oliver Jones (O)
Neil Mortensen (N)
Andrew Slater (A)
Aron Szuts (A)
Lai Wang (L)
Bryan Warren (B)
Andrew Weaver (A)
Mukhtar Ahmad (M)
Julian Alexander (J)
Maxine Flubacher (M)
David Tarver (D)
Suhail Baluch (S)
Richard Beable (R)
David Cowlishaw (D)
Antony Higginson (A)
Prokopios Vogiatzis (P)
Neil Cruickshank (N)
Howard Joy (H)
David Peake (D)
Ulises Zanetto (U)
Mark Saunders (M)
Arthur Sun-Myint (A)
Rajaram Sripadam (R)
Rachel Cooper (R)
Paul Hatfield (P)
Mark Teo (M)
Arthur Allan (A)
Ian Geh (I)
John Glaholm (J)
Mark Goldstein (M)
Rahul Hejmadi (R)
Gerald Langman (G)
Dion Morton (D)
Cyril Nelson (C)
Deborah Tattersall (D)
Stephen Falk (S)
Robert Longman (R)
Huw Roach (H)
Jamshed Shabbir (J)
Golda Shelley-Fraser (G)
Michael Thomas (M)
Neil Cripps (N)
Yasser Haba (Y)
Guy Harris (G)
Max Hookway (M)
Jay Simson (J)
Angela Skull (A)
Tijani Umar (T)

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Références

Lancet. 2017 Jul 29;390(10093):469-479
pubmed: 28601342
Br J Surg. 2009 Mar;96(3):280-90
pubmed: 19224520
Ann Surg Oncol. 2012 Feb;19(2):384-91
pubmed: 21755378
Surg Endosc. 2015 Apr;29(4):755-73
pubmed: 25609317
JAMA. 2014 Jan 15;311(3):263-70
pubmed: 24430319
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
Lancet Gastroenterol Hepatol. 2020 May;5(5):465-474
pubmed: 32043980
J Clin Oncol. 2012 Nov 1;30(31):3827-33
pubmed: 23008301
Br J Surg. 2006 Oct;93(10):1215-23
pubmed: 16983741
Lancet Oncol. 2010 Sep;11(9):835-44
pubmed: 20692872
Lancet. 2018 Jun 23;391(10139):2537-2545
pubmed: 29976470
Int J Radiat Oncol Biol Phys. 2020 Mar 1;106(3):556-563
pubmed: 31707122
Acta Oncol. 2016;55(4):502-8
pubmed: 26406287
Dis Colon Rectum. 2017 Mar;60(3):335-345
pubmed: 28177997
Colorectal Dis. 2017 Jul;19 Suppl 1:37-66
pubmed: 28632307
Dis Colon Rectum. 2016 Oct;59(10):984-97
pubmed: 27602930
J Clin Oncol. 1998 Jan;16(1):139-44
pubmed: 9440735
Cochrane Database Syst Rev. 2018 Oct 03;10:CD002102
pubmed: 30284239
Lancet Gastroenterol Hepatol. 2020 May;5(5):422-424
pubmed: 32043981
Lancet Oncol. 2015 Nov;16(15):1537-1546
pubmed: 26474521
Lancet Gastroenterol Hepatol. 2018 Dec;3(12):825-836
pubmed: 30318451
Int J Radiat Oncol Biol Phys. 2015 Jul 1;92(3):555-67
pubmed: 26068490
Eur J Cancer. 2009 Nov;45(17):3017-26
pubmed: 19765978
J Clin Oncol. 2005 May 20;23(15):3475-9
pubmed: 15908656
Int J Radiat Oncol Biol Phys. 2015 Jun 1;92(2):299-306
pubmed: 25772184
Br J Surg. 2016 Jul;103(8):1069-75
pubmed: 27146472
BMJ Open. 2017 Dec 28;7(12):e019474
pubmed: 29288190
Radiother Oncol. 1997 May;43(2):133-7
pubmed: 9192957
JAMA Surg. 2019 Jan 1;154(1):47-54
pubmed: 30304338
Br J Surg. 2015 Jun;102(7):853-60
pubmed: 25847025

Auteurs

Simon P Bach (SP)

Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK; Department of Colorectal Surgery, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. Electronic address: s.p.bach@bham.ac.uk.

Alexandra Gilbert (A)

Leeds Institute of Medical Research, University of Leeds, Leeds Cancer Centre, Leeds, UK.

Kristian Brock (K)

Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK.

Stephan Korsgen (S)

Department of Colorectal Surgery, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.

Ian Geh (I)

Department of Radiation Oncology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.

James Hill (J)

Department of Colorectal Surgery, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK.

Talvinder Gill (T)

Department of Colorectal Surgery, North Tees and Hartlepool NHS Foundation Trust, University Hospital of North Tees, Stockton-on-Tees, UK.

Paul Hainsworth (P)

Department of Colorectal Surgery, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.

Matthew G Tutton (MG)

Department of Colorectal Surgery, East Suffolk and North Essex NHS Foundation Trust, Colchester Hospital, Colchester, Essex, UK.

Jim Khan (J)

Department of Colorectal Surgery, Portsmouth Hospital NHS Trust, Portsmouth, UK.

Jonathan Robinson (J)

Department of Colorectal Surgery, Bradford Teaching Hospitals NHS Foundation Trust, Bradford, UK.

Mark Steward (M)

Department of Colorectal Surgery, Bradford Teaching Hospitals NHS Foundation Trust, Bradford, UK.

Christopher Cunningham (C)

Department of Colorectal Surgery, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Bruce Levy (B)

Department of Colorectal Surgery, Western Sussex Hospitals NHS Foundation Trust, West Sussex, UK.

Alan Beveridge (A)

Department of Colorectal Surgery, Lancashire Teaching Hospitals NHS Foundation Trust, Lancashire, UK.

Kelly Handley (K)

Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, UK.

Manjinder Kaur (M)

Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, UK.

Natalie Marchevsky (N)

Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, UK.

Laura Magill (L)

Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, UK.

Ann Russell (A)

Patient representative, National Cancer Research Institute, London, UK.

Philip Quirke (P)

Division of Pathology and Data Analytics, School of Medicine, Leeds University, Leeds, UK.

Nicholas P West (NP)

Division of Pathology and Data Analytics, School of Medicine, Leeds University, Leeds, UK.

David Sebag-Montefiore (D)

Leeds Institute of Medical Research, University of Leeds, Leeds Cancer Centre, Leeds, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH